A 2025 survey highlights growing momentum for multi-indication drug development, with opportunities in innovative trial ...

Ron Lanton, partner, Lanton Law, explains why evolving federal guidance and new technologies are pushing clinical operations teams to strengthen oversight and safeguard the credibility of clinical ...

Clinical trial updates in cancer care include a remote study in small cell lung cancer and new findings in ovarian, solid ...

Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR ...

On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 ...

Anxiety symptoms among U.S. adults, even during the COVID-19 pandemic, appear to have remained stable, according to a massive ...

Discover DiaMedica Therapeutics' Q2 2025 earnings call highlights: promising preeclampsia trial results, progress in stroke programs & a $60M extended ...

Selected patients with a clinical response after therapy could benefit from salvage surgery in non–small cell lung cancer (NSCLC), with acceptable results for perioperative morbidity.

Microchip-based platform enables real-time nerve mapping and targeted treatment from within the vascular system Continued progress toward submitting Investigational Device Exemption ("IDE"), and if ap ...

GCP compliance spans multiple parties; the article reviews their duties and proposes joint governance. By丨 Yongbin GE, ...

Discover Veru Inc.'s Q3 2025 earnings insights, including Phase III enobosarm trial updates, FDA feedback, and nondilutive funding plans for ...